Antibiotic susceptibility testing (AST) hasn’t seen true innovation in over 20+ years. All the while, bacteria have been evolving faster than science, creating resistance to lifesaving antibiotics.
According to the World Health Organization, antibiotic resistance is rising to dangerously high levels, becoming the next global health crisis. Selux is answering this call by creating a revolutionary AST system that outsmarts bacteria.
To preserve the lifesaving power of antibiotics for future generations we need faster diagnostic results, susceptibility testing on all sample types, testing against all commercially relevant antibiotics at one time, and a commitment to updated FDA and CLSI breakpoints.
Despite the importance of antimicrobial susceptibility testing (AST) to infectious diseases patient care, current AST systems either limit result speed, accuracy, or consistency. This forces an overreliance on broad-spectrum antibiotics and contributes to antimicrobial resistance. While multiple rapid AST technologies are under development, these are restricted to bloodstream infections so they cannot address the vast majority of hospitalized patients with other infections. The Selux NGP System offers same shift results, on all sample types.